Table 3.
Response to lenalidomide in patients with diffuse large B-cell lymphoma in first-line treatment.
| Name of the protocol | R2-CHOP [56] | LR-CHOP21 [57] | R2-CHOP [58] | |
| Year of publication | 2011 | 2010 | 2011 | |
|
| ||||
| Type of study | Monocentric | Multicentric-IIL | Multicentric | |
| Phase | Phase I | Phase I-II | Phase I-II | |
| Treatment | Lenalidomide and R-CHOP21 | Lenalidomide and R-CHOP21 | LenalidomideandR-CHOP21 | |
| Dose of lenalidomide: | 15 to 25 mg/d, D1–10 | 5 to 20 mg/d, D1–14 | 5 to 25 mg/d, D1–14 | |
| every 21 days | every 21 days | every 21 days | ||
| No. of cycles | 6 | 6 | 6 | |
| No. of patients with DLBCL |
24 | 21 | 27 | |
| Recommended dose in function of DLT |
25 mg | 15 mg | 25 mg | |
| Toxicity | ||||
| Hematologic | Grade III-IV | Grade III-IV | Grade III-IV | |
| Anemia | 21% | 4% | — | |
| Neutropenia | 88% | 28% | 59% | |
| Thrombocytopenia | 29% | 10% | 30% | |
| Grade III | Grade III | Grade I-II | Grade III | |
| Peripheral neurotoxicity | 8% | 14% | 48% | 0% |
| Vascular thrombosis | 8% | 7% | ||
| Response | ||||
| ORR n, (%) | 22 (87.5) | 16 (72) | 27 (100) | |
| CR n, (%) | 18 (77) | 15 (71) | 20 (74) | |
| PR n, (%) | 1 (5) | 7 (26) | ||
| Stable disease n, (%) | — | |||
| Progression n, (%) | 5 (21) | 5 (16) | — | |
R-CHOP: rituximab 375 mg/m2 D1, cyclophosphamide 750 mg/m2 D1, doxorubicin 50 mg/m2 D1, vincristine 1.4 mg/m2 D1 (capped at 2.0 mg) prednisone 50 mg/m2 D1–5.
DTL: dose limiting toxicity.